{
  "docId": "019de075-e8f5-748b-98ae-3f4a3c3c68f5",
  "docSlug": "5bc6ecf6756c39ce2bfe560c6ffb0fc7",
  "documentTitle": "ATAI | Investor Presentation Deck | 31 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 31,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes Cohen's d effect sizes and qEEG data markers.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e8f5-748b-98ae-3f4a3c3c68f5/10",
  "deckHref": "/decks/019de075-e8f5-748b-98ae-3f4a3c3c68f5",
  "deckJsonHref": "/decks/019de075-e8f5-748b-98ae-3f4a3c3c68f5.json",
  "deckAnchorHref": "/decks/019de075-e8f5-748b-98ae-3f4a3c3c68f5#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.1,
        "x": 0.88,
        "y": 0.045
      },
      "kind": "callout",
      "text": "Signal of improvement: Cohen's d* (Symbol Coding): 20 mg: 0.79, 40 mg: 0.56, 80 mg: 0.38",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4cbd1249-adc6-4f7b-aea9-09506f994b7f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.45,
        "x": 0.5,
        "y": 0.18
      },
      "kind": "chart",
      "text": "PHASE 2a TRIAL - EFFICACY DATA ON COMPONENTS MCCB COMPOSITE",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "75d76402-16d6-4b48-a7d2-a481bb5213f4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.03,
        "y": 0.55
      },
      "kind": "list",
      "text": "1. Study demonstrated dose-related trends for improvements on each MCCB neurocognitive endpoints. 2. Symbol Coding is the most sensitive subcomponent. 3. qEEG data was consistent with prior clinical evidence.",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "663f60a6-bdaa-40cb-86e5-d33a69be3707",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.03,
        "y": 0.1
      },
      "kind": "paragraph",
      "text": "atai's Phase 2a study in CIAS demonstrated positive cognitive signals on a subset of MCCB neurocognitive endpoints",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03634639-7a16-49f1-8568-a65cb5cf9908",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.03,
        "y": 0.17
      },
      "kind": "paragraph",
      "text": "Background: Cognitive function was assessed in 31 patients with CIAS across four RL-007 cohorts (10, 20, 40 & 80mg). The primary objectives were to confirm safety and identify signals of cognitive benefit.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e3ba8ec-0242-4e0e-ab02-8311f571a122",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Clinical Evidence: Efficacy Signals Reproduced in Phase 2a Study in CIAS",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ffcc5e46-85f7-4b30-8c59-7bae40546b2c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 25,
      "from": 6,
      "beatId": "3567efa9-5c4b-4d3c-88d1-7a53a3a212bc",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The presentation showcases the progress and achievements of atai Life Sciences' drug development programs, including efficacy and safety data.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 25,
      "from": 6,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "70da09d2-e8b7-478f-a3d9-ef5654b6b7c9",
      "evidence": "The presentation presents data and results from clinical trials, demonstrating the potential for atai Life Sciences' treatments to become first and best-in-class.",
      "position": 1,
      "objective": "Showcase the potential for first and best-in-class treatments",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}